## Mohd-Hafiz Abdul-Aziz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6649291/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infectious Diseases, The, 2014, 14, 498-509.	4.6	745
2	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. Intensive Care Medicine, 2020, 46, 1127-1153.	3.9	504
3	Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 681-691.	2.5	308
4	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Medicine, 2016, 42, 1535-1545.	3.9	244
5	Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 136-153.	0.8	134
6	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	1.3	129
7	Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. Journal of Thoracic Disease, 2018, 10, S629-S641.	0.6	110
8	Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Annals of Intensive Care, 2012, 2, 37.	2.2	85
9	Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis*. Critical Care Medicine, 2018, 46, 236-243.	0.4	85
10	Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?. International Journal of Antimicrobial Agents, 2019, 53, 211-224.	1.1	68
11	Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?. Current Opinion in Anaesthesiology, 2020, 33, 71-82.	0.9	45
12	Prolonged administration of β-lactam antibiotics – a comprehensive review and critical appraisal. Swiss Medical Weekly, 2016, 146, w14368.	0.8	41
13	What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. Journal of Antimicrobial Chemotherapy, 2016, 71, 696-702.	1.3	37
14	What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?. Pharmaceutics, 2020, 12, 638.	2.0	33
15	Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range. Therapeutic Drug Monitoring, 2022, 44, 19-31.	1.0	31
16	Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. Journal of Antimicrobial Chemotherapy, 2016, 71, 521-530.	1.3	21
17	Low Flucloxacillin Concentrations in a Patient With Central Nervous System Infection. Annals of Pharmacotherapy, 2014, 48, 1380-1384.	0.9	20
18	Increasing ventilator surge capacity in COVID 19 pandemic: design, manufacture and in vitro–in vivo testing in anaesthetized healthy pigs of a rapid prototyped mechanical ventilator. BMC Research Notes. 2020, 13, 421.	0.6	19

Mohd-Hafiz Abdul-Aziz

#	Article	IF	CITATIONS
19	Defining Antibiotic Dosing in Lung Infections. Clinical Pulmonary Medicine, 2013, 20, 121-128.	0.3	18
20	Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 103-112.	1.5	18
21	Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clinical Pharmacokinetics, 2020, 59, 1237-1250.	1.6	18
22	Identifying "at-risk―patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections. Critical Care, 2017, 21, 283.	2.5	17
23	Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base. Current Opinion in Infectious Diseases, 2020, 33, 501-510.	1.3	16
24	Antibiotic dosing for multidrug-resistant pathogen pneumonia. Current Opinion in Infectious Diseases, 2017, 30, 231-239.	1.3	13
25	New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 693-708.	1.5	12
26	Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). International Journal of Antimicrobial Agents, 2021, 58, 106466.	1.1	12
27	Population Pharmacokinetics of Doripenem in Critically III Patients with Sepsis in a Malaysian Intensive Care Unit. Antimicrobial Agents and Chemotherapy, 2016, 60, 206-214.	1.4	11
28	Pharmacokinetic/Pharmacodynamics-Optimized Antimicrobial Therapy in Patients with Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 271-286.	0.8	10
29	Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. Antimicrobial Agents and Chemotherapy, 2021, 65, e0143821.	1.4	9
30	Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study). Clinical Pharmacokinetics, 2022, 61, 847-856.	1.6	8
31	Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). Therapeutic Drug Monitoring, 2019, 41, 703-713.	1.0	7
32	Population Pharmacokinetics of Vancomycin in Critically III Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study). Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0137721.	1.4	7
33	What Are the Predictors for Achieving Therapeutic Levetiracetam Serum Concentrations in Adult Neurological Patients?. Therapeutic Drug Monitoring, 2020, 42, 626-630.	1.0	6
34	Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report. International Journal of Antimicrobial Agents, 2021, 58, 106431.	1.1	5
35	Indonesian healthcare providers' perceptions and attitude on antimicrobial resistance, prescription and stewardship programs. Future Microbiology, 2022, 17, 363-375.	1.0	5
36	Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. Expert Review of Anti-Infective Therapy, 2022, 20, 963-979.	2.0	5

#	Article	IF	CITATIONS
37	Antimicrobial therapy during ECMO–Âcustomised dosing with therapeutic drug monitoring: The way to go?. Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 451-453.	0.6	4
38	Pharmacokinetics of Total and Unbound Cefazolin during Veno-Arterial Extracorporeal Membrane Oxygenation: A Case Report. Chemotherapy, 2019, 64, 115-118.	0.8	4
39	Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
40	Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2017, 19, 8-14.	0.0	4
41	Hospital-Based Antimicrobial Stewardship Programs Used in Low- and Middle-Income Countries: A Scoping Review. Microbial Drug Resistance, 2022, 28, 566-584.	0.9	4
42	Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients. Scientific Reports, 2022, 12, .	1.6	4
43	The role of antibiotic pharmacokinetic studies performed post-licensing. International Journal of Antimicrobial Agents, 2020, 56, 106165.	1.1	3
44	Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). Anaesthesia, Critical Care & Pain Medicine, 2022, , 101080.	0.6	3
45	Antibiotic Dosing During Extracorporeal Membrane Oxygenation. , 2018, , 151-171.		2
46	A case report: Community-acquired Pseudomonas aeruginosa necrotizing fasciitis in a morbidly obese diabetic young man can be fatal. IDCases, 2020, 22, e01001.	0.4	1
47	Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. Pharmacotherapy, 2020, 40, 713-717.	1.2	1
48	Applying Antimicrobial Pharmacokinetic Principles for Complex Patients: Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation and Renal Replacement Therapy. Current Infectious Disease Reports, 2021, 23, 1.	1.3	1
49	Clinical Pharmacy Considerations in ICU. , 2019, , 849-865.		0
50	Knowledge, perception, and antibiotic prescribing practice in the intensive care unit: Findings from the malaysian public setting. Journal of Pharmacy and Bioallied Sciences, 2020, 12, 804.	0.2	0